Vycor Medical Q3 revenue $514K (+31% YoY); posts GAAP operating profit of $32K

VYCOR MEDICAL INC

2025-Q3 EPS reported -$0.01 revenue$1,446,523

Q3 2025 revenue $513,792, up 31% YoY; Vycor Medical division up 32% to $492K, mostly US growth.
GAAP operating profit of $32,085 in Q3 vs. loss in prior year; non-GAAP operating profit $60,162.
Nine-month revenue $1,446,523 (+28% YoY); non-GAAP operating profit $166,262 vs. $27,021 in 2024.
Gross margin dipped to 88% (Q3) and 84% (9-month) from 90% due to validation costs and international mix.
Three new peer-reviewed papers on VBAS published; NeuroEyeCoach study validates home-based therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.